

treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether high-dose recombinant interferon alfa-2B or ipilimumab is more effective than pembrolizumab in treating patients with melanoma.

Condition or disease ()	Intervention/treatment ()	Phase ①
Metastatic Non-Cutaneous Melanoma	Biological: Ipilimumab	Phase 3
Non-Cutaneous <mark>Melanoma</mark>	Other: Laboratory Biomarker Analysis	
Recurrent <mark>Melanoma</mark> of the Skin	Biological: Pembrolizumab	
Recurrent Non-Cutaneous Melanoma	Other: Pharmacological Study	
Stage III Cutaneous Melanoma AJCC v7	Other: Quality-of-Life Assessment	
Stage III Mucosal Melanoma of the Head and Neck AJCC v7	Biological: Recombinant Interferon Alfa-	
Stage IIIA Cutaneous Melanoma AJCC v7	2b	
Stage IIIB Cutaneous Melanoma AJCC v7		
Stage IIIC Cutaneous Melanoma AJCC v7		
Stage IV Cutaneous Melanoma AJCC v6 and v7		

Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7	
Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7	
Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7	

Hide Detailed Description

Detailed Description:

PRIMARY OBJECTIVES:

I. To compare overall survival (OS) of patients with resected stage III and IV melanoma treated with physician/patient choice of either high dose interferon alfa-2b (recombinant interferon alfa-2b) or ipilimumab versus MK-3475 (pembrolizumab).

II. Among patients who are PD-L1 positive, to compare OS of patients with resected stage III and IV melanoma treated with physician/patient choice of either high dose interferon alfa-2b or ipilimumab versus MK-3475 (pembrolizumab).

III. To compare relapse-free survival (RFS) of patients with resected stage III and IV melanoma treated with physician/patient choice of either high dose interferon alfa-2b or ipilimumab to MK-3475 (pembrolizumab).

SECONDARY OBJECTIVES:

I. To estimate OS and RFS for patients who are PD-L1 negative or PD-L1 indeterminate in this population.

II. To compare OS and RFS of patients between the two arms within PD-L1 positive and negative subgroups and to look at the interaction between PD-L1 (positive versus negative) and treatment arm.

III. To assess the safety and tolerability of the regimens.

ADDITIONAL OBJECTIVES:

I. To bank tissue and whole blood in anticipation of future correlative studies in this patient population.

II. To evaluate PD-L1 expression through immunohistochemistry assay. III. To evaluate the effect of treatment-related side effects that may have an impact on the health-related domains of quality of life (QOL) using the Functional Assessment of Cancer Therapy (FACT)-Biological Response Modifiers (BRM), European Quality of Life Five Dimension Three Level Scale (EQ-5D-3L), and Functional Assessment of Chronic Illness Therapy Diarrhea (FACIT-D) between patients treated with physician/patient choice of either high-dose interferon alfa-2b or ipilimumab and MK-3475 (pembrolizumab).

IV. Pharmacokinetic (PK) and anti-drug antibody (ADA) testing will be performed on all patients receiving MK-3475 (pembrolizumab).

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I:

INDUCTION THERAPY: Patients receive high-dose recombinant interferon alfa-2B intravenously (IV) over 20 minutes on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for a total of 4 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive high-dose recombinant interferon alfa-2B subcutaneously (SC) on days 1, 3, and 5. Treatment repeats every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for 3 years in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, 6 and 12 weeks, every 3 months for 2 years, every 6 months for 3 years, and then every 12 months for 5 years.

Study Design

Go to 🔻

Study Type **1**: Interventional (Clinical Trial)

Estimated Enrollment (): 1378 participants

1/10/2019	10/2019 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanom	
	Allocation:	Randomized
	Intervention Model:	Parallel Assignment
	Masking:	Double (Participant, Investigator)
	Primary Purpose:	Treatment
	Official Title:	A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or
		Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
	Actual Study Start Date 1 :	October 15, 2015
Estimated	Primary Completion Date 1:	September 15, 2023

Resource links provided by the National Library of Medicine Image: NLM Genetics Home Reference related topics: Melanoma MedlinePlus related topics: Melanoma Drug Information available for: Interferon Interferon Alfa-2b Ipilimumab Pembrolizumab Genetic and Rare Diseases Information Center resources: Meuroendocrine Tumor Neuroepithelioma U.S. FDA Resources Meanoma

Arms and Interventions

Go to 🔻

rm ð	Intervention/treatme
ctive Comparator: Arm I (high-dose recombinant interferon alfa-2B, ipilimumab)	Biological: Ipilimumab
INDUCTION THERAPY: Patients receive high-dose recombinant interferon alfa-2B intravenously (IV) over 20	Given IV
minutes on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or	Other Names:
unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3	Anti-Cytotoxic
weeks for a total of 4 courses in the absence of disease progression or unacceptable toxicity.	T-Lymphocyte
MAINTENANCE THERAPY: Patients receive high-dose recombinant interferon alfa-2B subcutaneously (SC)	Associated
on days 1, 3, and 5. Treatment repeats every 6 weeks for up to 48 weeks in the absence of disease	Antigen-4
progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment	Monoclonal
repeats every 12 weeks for 3 years in the absence of disease progression or unacceptable toxicity.	Antibody
	• BMS-734016
	• MDX-010
	 MDX-CTLA4
	Yervoy
	Other: Laboratory Biomarker Analysis
	Correlative studie
	Other: Pharmacologi Study
	Correlative studie
	Other: Quality-of-Life
	Assessment Ancillary studies

	Other Name: Quality of Life Assessment
	Biological: Recombinant <mark>Interferon Alfa-2b</mark>
	Given IV and SC
	Other Names:
	 Alfatronol
	 Glucoferon
	 Heberon Alfa
	 IFN alpha-2B
	 Interferon alfa 2b
	 Interferon Alfa- 2B
	Interferon
	Alpha-2b
	Intron A
	• Sch 30500
	Urifron
	 Viraferon
Experimental: Arm II (pembrolizumab)	
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.	Other: Laboratory Biomarker Analysis Correlative studies
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological:
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names:
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: • Keytruda
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: • Keytruda • Lambrolizumab
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: • Keytruda • Lambrolizumab • MK-3475
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: • Keytruda • Lambrolizumab • MK-3475 • SCH 900475
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: • Keytruda • Lambrolizumab • MK-3475 • SCH 900475
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: • Keytruda • Lambrolizumab • MK-3475 • SCH 900475 Other: Pharmacological Study Correlative studies
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	 Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: Keytruda Lambrolizumab MK-3475 SCH 900475 Other: Pharmacological Study Correlative studies Other: Quality-of-Life Assessment
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52	 Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: Keytruda Lambrolizumab MK-3475 SCH 900475 Other: Pharmacological Study Correlative studies Other: Quality-of-Life Assessment Ancillary studies

Outcome Measures Go to 💌	
--------------------------	--

Primary Outcome Measures () :

1. Overall survival (OS) [Time Frame: From date of randomization to date of death due to any cause, assessed up to 5 years]

Cox regression models will be used to estimate hazard ratios and calculate confidence intervals to compare treatment arms in the PD-L1 negative subgroup. In addition, Cox regression models for OS will be used to estimate interaction terms between PD-L1 status and treatment arm. A restricted mean survival time analysis will be done as a supportive analysis.

2. Relapse-free survival (RFS) [Time Frame: From date of randomization to date of first documentation of progression or death due to any cause, assessed up to 5 years]

Cox regression models will be used to estimate hazard ratios and calculate confidence intervals to compare treatment arms in the PD-L1 negative subgroup. In addition, Cox regression models for RFS will be used to estimate interaction terms between PD-L1 status and treatment arm. A restricted mean survival time analysis will be done as a supportive analysis.

3. PD-L1 status [Time Frame: Baseline]

Cox regression models will be used to estimate hazard ratios and calculate confidence intervals to compare treatment arms in the PD-L1 negative subgroup. In addition, Cox regression models for OS and RFS will be used to estimate interaction terms between PD-L1 status and treatment arm.

Secondary Outcome Measures () :

1. Incidence of toxicity assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (CTCAE version 5.0 beginning April 1, 2018) [Time Frame: Up to 30 days after the last study drug administration]

Toxicity rates will be estimated with a 95% confidence interval.

2. Post-relapse therapy [Time Frame: Up to 10 years]

Data on therapy after relapse will be collected for three years after relapse (or until 10 years after registration maximum). Therapies will be categorized into one of two categories: systemic or local. Specific therapies after relapse will be tabulated and summarized. Therapy after relapse will be analyzed as a time-dependent variable in Cox regression analyses for the endpoint of OS after relapse.

3. BRAF mutation status [Time Frame: Baseline]

Pre-study BRAF mutation status on patients will be collected. BRAF mutation will be analyzed as a prognostic value as a covariate in Cox regression analyses and exponential-logistic cure regression models. In addition, BRAF mutation will be analyzed as a predictive factor by analyzing the interaction between mutation status and treatment in Cox regression models and in exponential-logistic cure regression model.

4. Long-term survival [Time Frame: Up to 10 years]

Exponential-logistic cure regression models will be used to examine the association between known prognostic factors, including stage, and long-term survivor/cure status, and survival for patients who are not long-term survivors/cured.

5. Change in quality of life [Time Frame: Baseline to up to 5 years]

The European Quality of Life Five Dimension Three Level Scale (EQ-5D-EL), Functional Assessment of Cancer Therapy-Biological Response Modifiers (FACT-BRM), Functional Assessment of Chronic Illness Therapy Diarrhea (FACIT-D), and Trial Outcome Index will be assessed at multiple time points. Longitudinal regression models (using mixed-effects models) will be used to evaluate changes over time.

Eligibility Criteria

Go to 🖉 🔻

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <u>Learn About Clinical Studies</u>.

Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- STEP 1 REGISTRATION:
- Patients must have completely resected melanoma of cutaneous origin or of unknown primary in order to be eligible for this study; patients must be classified as stage IIIA (N2a), IIIB, IIIC, or stage IV melanoma; patients with non-ulcerated T1b N1a disease are not eligible; patients with melanoma of mucosal or other non-cutaneous origin are eligible; patients with melanoma of ocular origin are not eligible; patients with a history of brain metastases are ineligible
- Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site; nodal, satellite/in-transit metastasis, distant metastases or disease in a prior complete lymphadenectomy basin must have been confirmed histologically by hematoxylin and eosin (H & E) stained slides
- Patients with multiple regional nodal basin involvement are eligible; gross or microscopic extracapsular nodal extension is permitted
- Patients at initial presentation of melanoma must undergo an adequate wide excision of the primary lesion, if present; patients with previously diagnosed melanoma must have had all current disease resected with pathologically negative margins and must have no evidence of disease at the primary site or must undergo re-resection of the primary site; a full lymphadenectomy meeting the criteria outlined is required for all node-positive patients including those with positive sentinel nodes; patients with recurrent disease who have had a prior complete lymphadenectomy fulfill this requirement as long as all recurrent disease has been resected; for all patients, all disease must have been resected with negative pathological margins and no clinical, radiologic, or pathological evidence of any incompletely resected melanoma; patients must be registered within 98 days of the last surgery performed to render the patient free of disease
- Patients must have available and be willing to submit a minimum of five unstained slides from primary, lymph node, or metastatic site to
 determine PD-L1 expression; the tumor tissue must be adequate for PD-L1 testing (defined as >= 100 tumor cells as confirmed by the
 treating institution's local pathologist); this must be documented by having a pathologist sign the S1404 Local Pathology Review form
 prior to step 1 registration; the specimens may come from an archived block but must be submitted within 20 days from cutting the slides
- Patients must be offered the opportunity to participate in specimen banking as outlined
- Patients must be willing to have blood draws for PK/ADA analysis as outlined, should the patient be randomized to the MK-3475 arm
- Patients may have received prior radiation therapy, including after the surgical resection; all adverse events associated with prior surgery
 and radiation therapy must have resolved to =< grade 1 prior to registration
- Patients must not have received neoadjuvant treatment for their melanoma; patients must not have had prior immunotherapy including, but not limited to ipilimumab, interferon alfa-2b, high dose IL-2, pegylated (PEG)-IFN, anti-PD-1, anti-PD-L1 intra-tumoral, or vaccine therapies; patients must not be planning to receive any of the prohibited therapies during the screening or treatment phases of the study
- Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, hormonal therapy, other chemotherapy, surgery or other therapy after step 2 registration
- All patients must have disease-free status documented by a complete physical examination and imaging studies within 42 days prior to
 registration; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) scan that is of
 diagnostic quality (with or without brain) or a CT of the chest, abdomen and pelvis; for patients with melanoma arising from the head and
 neck, dedicated neck imaging (CT with IV contrast or PET-CT through the region) is required; if the patient has had unknown primary with



disease in the axilla, neck imaging is required to assure region is clear of cancer; CT imaging should be done with intravenous contrast if there are no contraindications for it; any other clinically-indicated imaging studies if performed (e.g. bone scan) must show no evidence of disease


- All patients must have a CT or magnetic resonance imaging (MRI) of the brain within 90 days prior to registration; the brain CT or MRI should be performed with intravenous contrast (unless contraindicated)
- Absolute neutrophil count (ANC) >= 1,500 microliter (mcL) (within 42 days prior to registration)
- Platelets >= 100,000 mcL (within 42 days prior to registration)
- Hemoglobin >= 10 g/dL (within 42 days prior to registration)
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 42 days prior to registration)
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2 x IULN (within 42 days prior to registration)
- Alkaline phosphatase =< 2 x IULN (within 42 days prior to registration)
- Serum creatinine =< IULN OR measured or calculated creatinine clearance >= 60 mL/min (within 42 days prior to registration)
- Patients must have lactate dehydrogenase (LDH) performed within 42 days prior to registration
- Patients must have Zubrod performance status =< 1
- Patients must have a baseline electrocardiogram (ECG) performed within 42 days of registration that is normal or considered not clinically significant by the site investigator
- · Patients must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- · Patients must not have an active infection requiring systemic therapy
- Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- Patients must not have received live vaccines within 42 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
- Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate cluster of differentiation 4 (CD4) counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria
- Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
- Patients must not have a history or current evidence of any condition, therapy or laboratory abnormality that might confound the trial results, interfere with the patient's participation for the full duration of the trial, or indicate that participation in the trial is not in the patient's best interests, in the opinion of the treating investigator
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, lobular carcinoma of the breast in situ, atypical melanocytic hyperplasia or melanoma in situ, adequately treated stage I or II cancer (including multiple primary melanomas) from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years
- Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursing
- Patients who are able to complete questionnaires in English, Spanish or French must participate in the quality of life assessments; (those patients who cannot complete the quality of life questionnaires in English, Spanish or French can be registered to S1404 without

- 9 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th... contributing to the quality of life studies)
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- STEP 2 REGISTRATION (RANDOMIZATION CRITERIA):
- Patients must not be registered until receiving confirmation from the Southwest Oncology Group (SWOG) Statistical Center that the patient's tissue specimen was adequate for PD-L1 testing; patients must be registered within 7 working days of receiving the e-mail notification
- Women of childbearing potential must plan to have a urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a negative serum pregnancy test will be required
- No tests or exams are required to be repeated for step 2 registration (randomization); however, patients who are known to have a change in eligibility status after step 1 registration are not eligible for step 2 registration; for example, ANC is not required to be repeated between step 1 and step 2 registration, but the most recent ANC performed before step 2 registration is required to be >= 1,500 mcL

Go to

Ŧ

Contacts and Locations



Hide Study Locations

Locations

United States, Alabama

University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States, 35233

United States, Arizona

University of Arizona Cancer Center at Saint Joseph's Phoenix, Arizona, United States, 85004

Virginia G Piper Cancer Care-Del Camino Scottsdale, Arizona, United States, 85258

University of Arizona Cancer Center-North Campus Tucson, Arizona, United States, 85719

The University of Arizona Medical Center-University Campus Tucson, Arizona, United States, 85724

United States, Arkansas

University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205

Highlands Oncology Group-Rogers Rogers, Arkansas, United States, 72758

United States, California

Kaiser Permanente-Anaheim

Anaheim, California, United States, 92806
Sutter Auburn Faith Hospital
Auburn, California, United States, 95602
Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States, 91706
Kaiser Permanente-Bellflower Bellflower, California, United States, 90706
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, United States, 92627
City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010
Kaiser Permanente-Fontana
Fontana, California, United States, 92335
Kaiser Permanente-Fremont
Fremont, California, United States, 94538
Palo Alto Medical Foundation-Fremont
Fremont, California, United States, 94538
Kaiser Permanente-Fresno
Fresno, California, United States, 93720
Kaiser Permanente - Harbor City Harbor City, California, United States, 90710
Kaiser Permanente-Irvine Irvine, California, United States, 92618
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Kaiser Permanente Los Angeles Medical Center Los Angeles, California, United States, 90027
Los Angeles County-USC Medical Center
Los Angeles, California, United States, 90033
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Kaiser Permanente-Cadillac
Los Angeles, California, United States, 90034
Cedars Sinai Medical Center Los Angeles, California, United States, 90048
UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095
Fremont - Rideout Cancer Center
Marysville, California, United States, 95901
Memorial Medical Center Modesto, California, United States, 95355
Kaiser Permanente-Modesto
Modesto, California, United States, 95356
Palo Alto Medical Foundation-Camino Division
Mountain View, California, United States, 94040
USC Norris Oncology/Hematology-Newport Beach

1/10/2019

Newport Beach, California, United States, 92663

Sutter Cancer Research Consortium Novato, California, United States, 94945

Kaiser Permanente-Oakland Oakland, California, United States, 94611

Saint Joseph Hospital - Orange Orange, California, United States, 92868

UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States, 92868

Palo Alto Medical Foundation Health Care Palo Alto, California, United States, 94301

Stanford Cancer Institute Palo Alto Palo Alto, California, United States, 94304

Kaiser Permanente - Panorama City Panorama City, California, United States, 91402

- Kaiser Permanente-Redwood City Redwood City, California, United States, 94063
- Kaiser Permanente-Richmond Richmond, California, United States, 94801
- Kaiser Permanente-Riverside Riverside, California, United States, 92505
- Kaiser Permanente-Roseville Roseville, California, United States, 95661
- Sutter Roseville Medical Center Roseville, California, United States, 95661
- Sutter Medical Center Sacramento Sacramento, California, United States, 95816
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817

Kaiser Permanente-South Sacramento Sacramento, California, United States, 95823

- Kaiser Permanente Sacramento Sacramento, California, United States, 95825
- Kaiser Permanente-San Diego Mission San Diego, California, United States, 92108
- Kaiser Permanente-San Diego Zion San Diego, California, United States, 92120
- California Pacific Medical Center-Pacific Campus San Francisco, California, United States, 94115
- Kaiser Permanente-San Francisco San Francisco, California, United States, 94115
- Kaiser Permanente-Santa Teresa-San Jose San Jose, California, United States, 95119

Kaiser Permanente San Leandro San Leandro, California, United States, 94577

Kaiser Permanente-San Marcos San Marcos, California, United States, 92078

Kaiser Permanente-San Rafael

1/10/201	9
----------	---

San Rafael, California, United States, 94903

Kaiser Permanente Medical Center - Santa Clara Santa Clara, California, United States, 95051

Palo Alto Medical Foundation-Santa Cruz Santa Cruz, California, United States, 95065

Kaiser Permanente-Santa Rosa Santa Rosa, California, United States, 95403

Sutter Pacific Medical Foundation Santa Rosa, California, United States, 95403

Kaiser Permanente-South San Francisco South San Francisco, California, United States, 94080

Kaiser Permanente-Stockton Stockton, California, United States, 95210

Palo Alto Medical Foundation-Sunnyvale Sunnyvale, California, United States, 94086

Gene Upshaw Memorial Tahoe Forest Cancer Center Truckee, California, United States, 96161

Kaiser Permanente Medical Center-Vacaville Vacaville, California, United States, 95688

Kaiser Permanente-Vallejo Vallejo, California, United States, 94589

Kaiser Permanente-Walnut Creek Walnut Creek, California, United States, 94596

Kaiser Permanente-Woodland Hills Woodland Hills, California, United States, 91367

United States, Colorado

University of Colorado Hospital Aurora, Colorado, United States, 80045

Penrose-Saint Francis Healthcare Colorado Springs, Colorado, United States, 80907

UCHealth Memorial Hospital Central Colorado Springs, Colorado, United States, 80909

Kaiser Permanente-Franklin

Denver, Colorado, United States, 80205

Porter Adventist Hospital

Denver, Colorado, United States, 80210

SCL Health Saint Joseph Hospital

Denver, Colorado, United States, 80218

Poudre Valley Hospital

Fort Collins, Colorado, United States, 80524

North Colorado Medical Center

Greeley, Colorado, United States, 80631

Kaiser Permanente-Rock Creek Lafayette, Colorado, United States, 80026

Littleton Adventist Hospital Littleton, Colorado, United States, 80122

Kaiser Permanente-Lone Tree

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th...

Lone Tree, Colorado, United States, 80124

Parker Adventist Hospital Parker, Colorado, United States, 80138

United States, Connecticut

Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States, 06824

Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States, 06105

Yale University

New Haven, Connecticut, United States, 06520

Stamford Hospital/Bennett Cancer Center Stamford, Connecticut, United States, 06904

Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut, United States, 06611

United States, Delaware

Helen F Graham Cancer Center Newark, Delaware, United States, 19713

Medical Oncology Hematology Consultants PA Newark, Delaware, United States, 19713

Regional Hematology and Oncology PA Newark, Delaware, United States, 19713

Christiana Care Health System-Christiana Hospital Newark, Delaware, United States, 19718

Beebe Health Campus Rehoboth Beach, Delaware, United States, 19971

United States, District of Columbia

MedStar Georgetown University Hospital Washington, District of Columbia, United States, 20007

MedStar Washington Hospital Center Washington, District of Columbia, United States, 20010

United States, Florida

Lakeland Regional Health Hollis Cancer Center Lakeland, Florida, United States, 33805

Mount Sinai Medical Center Miami Beach, Florida, United States, 33140

University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States, 33136

UF Cancer Center at Orlando Health Orlando, Florida, United States, 32806

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Cleveland Clinic-Weston Weston, Florida, United States, 33331

United States, Georgia

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States, 30322

Northside Hospital Atlanta, Georgia, United States, 30342 Northside Hospital-Forsyth Cumming, Georgia, United States, 30041 Memorial Health University Medical Center Savannah, Georgia, United States, 31404 Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah, Georgia, United States, 31405

South Georgia Medical Center/Pearlman Cancer Center Valdosta, Georgia, United States, 31602

United States, Hawaii

Hawaii Cancer Care Inc-POB II Honolulu, Hawaii, United States, 96813

Hawaii Oncology Inc-POB I Honolulu, Hawaii, United States, 96813

Island Urology

Honolulu, Hawaii, United States, 96813

Queen's Medical Center

Honolulu, Hawaii, United States, 96813

Straub Clinic and Hospital

Honolulu, Hawaii, United States, 96813

University of Hawaii Cancer Center Honolulu, Hawaii, United States, 96813

Hawaii Cancer Care Inc-Liliha Honolulu, Hawaii, United States, 96817

Hawaii Oncology Inc-Kuakini Honolulu, Hawaii, United States, 96817

Tripler Army Medical Center Honolulu, Hawaii, United States, 96859

United States, Idaho

Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States, 83706

Saint Luke's Mountain States Tumor Institute Boise, Idaho, United States, 83712

Kootenai Medical Center Coeur d'Alene, Idaho, United States, 83814

Saint Luke's Mountain States Tumor Institute - Fruitland Fruitland, Idaho, United States, 83619

Saint Luke's Mountain States Tumor Institute - Meridian Meridian, Idaho, United States, 83642

Saint Luke's Mountain States Tumor Institute - Nampa Nampa, Idaho, United States, 83686

Kootenai Cancer Center Post Falls, Idaho, United States, 83854

Kootenai Cancer Clinic Sandpoint, Idaho, United States, 83864

Saint Luke's Mountain States Tumor Institute-Twin Falls Twin Falls, Idaho, United States, 83301

United States, Illinois

Rush - Copley Medical Center Aurora, Illinois, United States, 60504

Illinois CancerCare-Bloomington

Bloomington, Illinois, United States, 61704

Illinois CancerCare-Canton

Canton, Illinois, United States, 61520

Centralia Oncology Clinic Centralia, Illinois, United States, 62801

Northwestern University

Chicago, Illinois, United States, 60611

- Rush University Medical Center Chicago, Illinois, United States, 60612
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637
- Carle on Vermilion

Danville, Illinois, United States, 61832

Cancer Care Specialists of Illinois - Decatur Decatur, Illinois, United States, 62526

Decatur Memorial Hospital

Decatur, Illinois, United States, 62526

- Carle Physician Group-Effingham Effingham, Illinois, United States, 62401
- Crossroads Cancer Center Effingham, Illinois, United States, 62401

Elmhurst Memorial Hospital Elmhurst, Illinois, United States, 60126

Illinois CancerCare-Eureka Eureka, Illinois, United States, 61530

- NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States, 60201
- Illinois CancerCare-Galesburg Galesburg, Illinois, United States, 61401

Northwestern Medicine Cancer Center Delnor Geneva, Illinois, United States, 60134

- NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois, United States, 60026
- NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois, United States, 60035
- Illinois CancerCare-Kewanee Clinic Kewanee, Illinois, United States, 61443
- Illinois CancerCare-Macomb

Macomb, Illinois, United States, 61455

Carle Physician Group-Mattoon/Charleston Mattoon, Illinois, United States, 61938

1/10/2019	
-----------	--

Loyola University Medical Center Maywood, Illinois, United States, 60153

Edward Hospital/Cancer Center Naperville, Illinois, United States, 60540

UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois, United States, 60451

University of Chicago Medicine-Orland Park Orland Park, Illinois, United States, 60462

Illinois CancerCare-Ottawa Clinic Ottawa, Illinois, United States, 61350

Illinois CancerCare-Pekin

Pekin, Illinois, United States, 61554

Illinois CancerCare-Peoria

Peoria, Illinois, United States, 61615

Illinois CancerCare-Peru

Peru, Illinois, United States, 61354

Edward Hospital/Cancer Center?Plainfield Plainfield, Illinois, United States, 60585

Illinois CancerCare-Princeton Princeton, Illinois, United States, 61356

SwedishAmerican Regional Cancer Center/ACT Rockford, Illinois, United States, 61114

Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 62702

Southern Illinois University School of Medicine Springfield, Illinois, United States, 62702

Springfield Clinic

Springfield, Illinois, United States, 62702

Memorial Medical Center

Springfield, Illinois, United States, 62781

Cancer Care Specialists of Illinois-Swansea Swansea, Illinois, United States, 62226

Carle Cancer Center

Urbana, Illinois, United States, 61801

The Carle Foundation Hospital Urbana, Illinois, United States, 61801

Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois, United States, 60555

Rush-Copley Healthcare Center Yorkville, Illinois, United States, 60560

United States, Indiana

Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202

Community Cancer Center East Indianapolis, Indiana, United States, 46219

Community Cancer Center South Indianapolis, Indiana, United States, 46227

Franciscan Health Indianapolis Indianapolis, Indiana, United States, 46237

Community Cancer Center North Indianapolis, Indiana, United States, 46256

Franciscan Health Mooresville Mooresville, Indiana, United States, 46158

Reid Health

Richmond, Indiana, United States, 47374

United States, Iowa

Mary Greeley Medical Center Ames, Iowa, United States, 50010

McFarland Clinic PC - Ames Ames, Iowa, United States, 50010

McFarland Clinic PC-Boone Boone, Iowa, United States, 50036

Physicians' Clinic of Iowa PC Cedar Rapids, Iowa, United States, 52402

Medical Oncology and Hematology Associates-West Des Moines Clive, Iowa, United States, 50325

Mercy Cancer Center-West Lakes Clive, Iowa, United States, 50325

Iowa Methodist Medical Center Des Moines, Iowa, United States, 50309

Medical Oncology and Hematology Associates-Des Moines Des Moines, Iowa, United States, 50309

Medical Oncology and Hematology Associates-Laurel Des Moines, Iowa, United States, 50314

Mercy Medical Center - Des Moines Des Moines, Iowa, United States, 50314

McFarland Clinic PC-Trinity Cancer Center Fort Dodge, Iowa, United States, 50501

University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States, 52242

McFarland Clinic PC-Jefferson Jefferson, Iowa, United States, 50129

McFarland Clinic PC-Marshalltown Marshalltown, Iowa, United States, 50158

Mercy Medical Center-West Lakes West Des Moines, Iowa, United States, 50266

United States, Kansas

Cancer Center of Kansas - Chanute Chanute, Kansas, United States, 66720

Cancer Center of Kansas - Dodge City Dodge City, Kansas, United States, 67801

Cancer Center of Kansas - El Dorado El Dorado, Kansas, United States, 67042

1/1	0/2019	
-----	--------	--

riigh-bose Recombinant interieron Alia-2D, ipilindinab, or re	11
Saint Catherine Hospital Garden City, Kansas, United States, 67846	
Central Care Cancer Center - Great Bend Great Bend, Kansas, United States, 67530	
Saint Rose Ambulatory and Surgery Center Great Bend, Kansas, United States, 67530	
Hays Medical Center Hays, Kansas, United States, 67601	
University of Kansas Cancer Center-West Kansas City, Kansas, United States, 66112	
University of Kansas Cancer Center Kansas City, Kansas, United States, 66160	
Lawrence Memorial Hospital Lawrence, Kansas, United States, 66044	
Kansas Institute of Medicine Cancer and Blood Center Lenexa, Kansas, United States, 66219	
Minimally Invasive Surgery Hospital Lenexa, Kansas, United States, 66219	
Cancer Center of Kansas-Liberal Liberal, Kansas, United States, 67905	
Cancer Center of Kansas - McPherson McPherson, Kansas, United States, 67460	
Cancer Center of Kansas - Newton Newton, Kansas, United States, 67114	
Olathe Medical Center Olathe, Kansas, United States, 66061	
Menorah Medical Center Overland Park, Kansas, United States, 66209	
University of Kansas Cancer Center-Overland Park Overland Park, Kansas, United States, 66210	
Saint Luke's South Hospital Overland Park, Kansas, United States, 66213	
Cancer Center of Kansas - Parsons Parsons, Kansas, United States, 67357	
Via Christi Hospital-Pittsburg Pittsburg, Kansas, United States, 66762	
Cancer Center of Kansas - Salina Salina, Kansas, United States, 67401	
Salina Regional Health Center Salina, Kansas, United States, 67401	
Saint Francis Hospital and Medical Center - Topeka Topeka, Kansas, United States, 66606	
Cancer Center of Kansas - Wellington Wellington, Kansas, United States, 67152	
Cancer Center of Kansas-Wichita Medical Arts Tower Wichita, Kansas, United States, 67208	

Wichita, Kansas, United States, 67214

Via Christi Regional Medical Center Wichita, Kansas, United States, 67214

Cancer Center of Kansas - Winfield Winfield, Kansas, United States, 67156

United States, Kentucky

Flaget Memorial Hospital Bardstown, Kentucky, United States, 40004

Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky, United States, 40504

Saint Joseph Hospital East Lexington, Kentucky, United States, 40509

Saints Mary and Elizabeth Hospital Louisville, Kentucky, United States, 40215

Jewish Hospital Medical Center Northeast Louisville, Kentucky, United States, 40245

Owensboro Health Mitchell Memorial Cancer Center Owensboro, Kentucky, United States, 42303

United States, Louisiana

LSU Health Baton Rouge-North Clinic Baton Rouge, Louisiana, United States, 70805

Louisiana Hematology Oncology Associates LLC Baton Rouge, Louisiana, United States, 70809

Mary Bird Perkins Cancer Center Baton Rouge, Louisiana, United States, 70809

Our Lady of the Lake Physicians Group - Medical Oncology Baton Rouge, Louisiana, United States, 70809

Northshore Oncology Associates-Covington Covington, Louisiana, United States, 70433

University Health-Conway Monroe, Louisiana, United States, 71202

Louisiana State University Health Sciences Center Shreveport Shreveport, Louisiana, United States, 71103

United States, Maine

Harold Alfond Center for Cancer Care Augusta, Maine, United States, 04330

Eastern Maine Medical Center Bangor, Maine, United States, 04401 Lafayette Family Cancer Center-EMMC

Brewer, Maine, United States, 04412

Maine Center for Cancer Medicine-Scarborough Scarborough, Maine, United States, 04074

United States, Maryland

Mercy Medical Center Baltimore, Maryland, United States, 21202

MedStar Franklin Square Medical Center/Weinberg Cancer Institute

1/10/2019	High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th
	Baltimore, Maryland, United States, 21237
	Frederick Memorial Hospital
	Frederick, Maryland, United States, 21701
Uni	ted States, Massachusetts
	Beverly Hospital
	Beverly, Massachusetts, United States, 01915
	Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114
	Boston Medical Center
	Boston, Massachusetts, United States, 02118
	Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215
	Dana-Farber Cancer Institute
	Boston, Massachusetts, United States, 02215
	Lahey Hospital and Medical Center Burlington, Massachusetts, United States, 01805
	Addison Gilbert Hospital
	Gloucester, Massachusetts, United States, 01930
	Baystate Medical Center Springfield, Massachusetts, United States, 01199
Uni	ted States, Michigan
	University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109
	Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201
	Henry Ford Hospital Detroit, Michigan, United States, 48202
	Ascension Saint John Hospital Detroit, Michigan, United States, 48236
	Great Lakes Cancer Management Specialists-Doctors Park East China Township, Michigan, United States, 48054
	Green Bay Oncology - Escanaba
	Escanaba, Michigan, United States, 49829
	Genesys Hurley Cancer Institute
	Flint, Michigan, United States, 48503
	Hurley Medical Center Flint, Michigan, United States, 48503
	Mercy Health Saint Mary's Grand Rapids, Michigan, United States, 49503
	Spectrum Health at Butterworth Campus Grand Rapids, Michigan, United States, 49503
	Great Lakes Cancer Management Specialists-Van Elslander Cancer Center Grosse Pointe Woods, Michigan, United States, 48236
	Lymphoma Clinic of Michigan Grosse Pointe Woods, Michigan, United States, 48236

Michigan Breast Specialists-Grosse Pointe Woods

1/10/2019	High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th
	Grosse Pointe Woods, Michigan, United States, 48236
	Green Bay Oncology - Iron Mountain
	Iron Mountain, Michigan, United States, 49801
	Allegiance Health
	Jackson, Michigan, United States, 49201
	West Michigan Cancer Center
	Kalamazoo, Michigan, United States, 49007
	Sparrow Hospital
	Lansing, Michigan, United States, 48912
	Great Lakes Cancer Management Specialists-Macomb Medical Campus Macomb, Michigan, United States, 48044
	Michigan Breast Specialists-Macomb Township
	Macomb, Michigan, United States, 48044
	Mercy Health Mercy Campus
	Muskegon, Michigan, United States, 49444
	Spectrum Health Reed City Hospital
	Reed City, Michigan, United States, 49677
	Great Lakes Cancer Management Specialists-Rochester Hills
	Rochester Hills, Michigan, United States, 48309
	Saint Mary's of Michigan Saginaw, Michigan, United States, 48601
	Munson Medical Center
	Traverse City, Michigan, United States, 49684
	Great Lakes Cancer Management Specialists-Macomb Professional Building
	Warren, Michigan, United States, 48093
	Saint John Macomb-Oakland Hospital
	Warren, Michigan, United States, 48093
	Metro Health Hospital
	Wyoming, Michigan, United States, 49519
Uni	ted States, Minnesota
	Sanford Joe Lueken Cancer Center
	Bemidji, Minnesota, United States, 56601
	Fairview Ridges Hospital
	Burnsville, Minnesota, United States, 55337
	Mercy Hospital
	Coon Rapids, Minnesota, United States, 55433
	Essentia Health Cancer Center Duluth, Minnesota, United States, 55805
	Essentia Health Saint Mary's Medical Center Duluth, Minnesota, United States, 55805
	Miller-Dwan Hospital
	Duluth, Minnesota, United States, 55805
	Fairview-Southdale Hospital
	Edina, Minnesota, United States, 55435
	Lake Region Healthcare Corporation-Cancer Care
	Fergus Falls, Minnesota, United States, 56537
	Unity Hospital

1/	10	/20	19
• • •	10	120	10

Fridley, Minnesota, United States, 55432

Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota, United States, 55109

Saint John's Hospital - Healtheast Maplewood, Minnesota, United States, 55109

Abbott-Northwestern Hospital

Minneapolis, Minnesota, United States, 55407

Hennepin County Medical Center Minneapolis, Minnesota, United States, 55415

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, United States, 55416

Regions Hospital

Saint Paul, Minnesota, United States, 55101

United Hospital

Saint Paul, Minnesota, United States, 55102

Ridgeview Medical Center Waconia, Minnesota, United States, 55387 Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, United States, 55125

United States, Mississippi

University of Mississippi Medical Center Jackson, Mississippi, United States, 39216

United States, Missouri

Parkland Health Center-Bonne Terre Bonne Terre, Missouri, United States, 63628

Saint Francis Medical Center Cape Girardeau, Missouri, United States, 63703

Southeast Cancer Center Cape Girardeau, Missouri, United States, 63703

Centerpoint Medical Center LLC Independence, Missouri, United States, 64057

- Capital Region Southwest Campus Jefferson City, Missouri, United States, 65109
- Truman Medical Center Kansas City, Missouri, United States, 64108

Saint Luke's Hospital of Kansas City Kansas City, Missouri, United States, 64111

- Heartland Hematology and Oncology Associates Incorporated Kansas City, Missouri, United States, 64118
- Kansas City Veterans Affairs Medical Center Kansas City, Missouri, United States, 64128

The University of Kansas Cancer Center-South Kansas City, Missouri, United States, 64131

Research Medical Center

Kansas City, Missouri, United States, 64132

The University of Kansas Cancer Center-North

Kansas City, Missouri, United States, 64154	
The University of Kansas Cancer Center-Lee's Summit Lee's Summit, Missouri, United States, 64064	
Saint Luke's East - Lee's Summit Lee's Summit, Missouri, United States, 64086	
Liberty Radiation Oncology Center Liberty, Missouri, United States, 64068	
Heartland Regional Medical Center Saint Joseph, Missouri, United States, 64507	
Missouri Baptist Medical Center Saint Louis, Missouri, United States, 63131	
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri, United States, 63670	
Mercy Hospital Springfield Springfield, Missouri, United States, 65804	
CoxHealth South Hospital Springfield, Missouri, United States, 65807	
Missouri Baptist Sullivan Hospital Sullivan, Missouri, United States, 63080	
United States, Montana	
Community Hospital of Anaconda Anaconda, Montana, United States, 59711	
Billings Clinic Cancer Center Billings, Montana, United States, 59101	
Saint Vincent Healthcare Billings, Montana, United States, 59101	
Bozeman Deaconess Hospital Bozeman, Montana, United States, 59715	
Saint James Community Hospital and Cancer Treatment Center Butte, Montana, United States, 59701	
Benefis Healthcare- Sletten Cancer Institute Great Falls, Montana, United States, 59405	
Great Falls Clinic Great Falls, Montana, United States, 59405	
Saint Peter's Community Hospital Helena, Montana, United States, 59601	
Kalispell Regional Medical Center Kalispell, Montana, United States, 59901	
Saint Patrick Hospital - Community Hospital Missoula, Montana, United States, 59802	
Community Medical Hospital Missoula, Montana, United States, 59804	
United States, Nebraska	
CHI Health Saint Francis	

Grand Island, Nebraska, United States, 68803 Nebraska Hematology and Oncology

1/10/2019

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th...

Lincoln, Nebraska, United States, 68506

Southeast Nebraska Cancer Center Lincoln, Nebraska, United States, 68510

Faith Regional Health Services Carson Cancer Center Norfolk, Nebraska, United States, 68701

Nebraska Methodist Hospital

Omaha, Nebraska, United States, 68114

Alegent Health Immanuel Medical Center Omaha, Nebraska, United States, 68122

Alegent Health Bergan Mercy Medical Center Omaha, Nebraska, United States, 68124

Nebraska Cancer Specialists - Omaha Omaha, Nebraska, United States, 68124

Alegent Health Lakeside Hospital Omaha, Nebraska, United States, 68130

Creighton University Medical Center Omaha, Nebraska, United States, 68131

Regional West Medical Center Cancer Center Scottsbluff, Nebraska, United States, 69361

United States, Nevada

Cancer and Blood Specialists-Henderson Henderson, Nevada, United States, 89052

Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada, United States, 89052

Las Vegas Cancer Center-Henderson Henderson, Nevada, United States, 89052

21st Century Oncology-Henderson Henderson, Nevada, United States, 89074

Comprehensive Cancer Centers of Nevada-Southeast Henderson Henderson, Nevada, United States, 89074

University Medical Center of Southern Nevada Las Vegas, Nevada, United States, 89102

21st Century Oncology

Las Vegas, Nevada, United States, 89109

Cancer Therapy and Integrative Medicine Las Vegas, Nevada, United States, 89121

Ann M Wierman MD LTD

Las Vegas, Nevada, United States, 89128

Comprehensive Cancer Centers of Nevada - Northwest Las Vegas, Nevada, United States, 89128

Las Vegas Cancer Center-Medical Center

Las Vegas, Nevada, United States, 89148-2405

Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89148

OptumCare Cancer Care at Fort Apache Las Vegas, Nevada, United States, 89148

Comprehensive Cancer Centers of Nevada - Central Valley

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th...

Las Vegas, Nevada, United States, 89169

University Cancer Center Las Vegas, Nevada, United States, 89169

United States, New Hampshire

Wentworth-Douglass Hospital Dover, New Hampshire, United States, 03820

Dartmouth Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756

Norris Cotton Cancer Center-Manchester Manchester, New Hampshire, United States, 03102

Saint Joseph Hospital Nashua, New Hampshire, United States, 03060

Norris Cotton Cancer Center-Nashua Nashua, New Hampshire, United States, 03063

United States, New Jersey

Veterans Adminstration New Jersey Health Care System East Orange, New Jersey, United States, 07018-1095

Hackensack University Medical Center Hackensack, New Jersey, United States, 07601

Saint Barnabas Medical Center Livingston, New Jersey, United States, 07039

Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903

United States, New Mexico

Lovelace Medical Center-Saint Joseph Square Albuquerque, New Mexico, United States, 87102

University of New Mexico Cancer Center Albuquerque, New Mexico, United States, 87102

Southwest Gynecologic Oncology Associates Inc Albuquerque, New Mexico, United States, 87106

United States, New York

Hematology Oncology Associates of Central New York-Auburn Auburn, New York, United States, 13021

Roswell Park Cancer Institute Buffalo, New York, United States, 14263

Hematology Oncology Associates of Central New York-East Syracuse

East Syracuse, New York, United States, 13057

Glens Falls Hospital

Glens Falls, New York, United States, 12801

Columbia University/Herbert Irving Cancer Center New York, New York, United States, 10032

Rochester General Hospital

Rochester, New York, United States, 14621

University of Rochester

Rochester, New York, United States, 14642

Stony Brook University Medical Center

Stony Brook, New York, United States, 11794

State University of New York Upstate Medical University Syracuse, New York, United States, 13210

Hematology Oncology Associates of Central New York-Onondaga Hill Syracuse, New York, United States, 13215

United States, North Carolina

UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599

Southeastern Medical Oncology Center-Clinton Clinton, North Carolina, United States, 28328

Duke University Medical Center Durham, North Carolina, United States, 27710

Southeastern Medical Oncology Center-Goldsboro Goldsboro, North Carolina, United States, 27534

Wayne Memorial Hospital

Goldsboro, North Carolina, United States, 27534

Hendersonville Hematology and Oncology at Pardee Hendersonville, North Carolina, United States, 28791

Margaret R Pardee Memorial Hospital Hendersonville, North Carolina, United States, 28791

Southeastern Medical Oncology Center-Jacksonville Jacksonville, North Carolina, United States, 28546

Southeastern Medical Oncology Center-Wilson Wilson, North Carolina, United States, 27893

United States, North Dakota

Sanford Bismarck Medical Center Bismarck, North Dakota, United States, 58501

Roger Maris Cancer Center Fargo, North Dakota, United States, 58122

Sanford Broadway Medical Center Fargo, North Dakota, United States, 58122

Sanford Clinic North-Fargo Fargo, North Dakota, United States, 58122

Altru Cancer Center Grand Forks, North Dakota, United States, 58201

United States, Ohio

UHHS-Chagrin Highlands Medical Center Beachwood, Ohio, United States, 44122

Strecker Cancer Center-Belpre

Belpre, Ohio, United States, 45714

Dayton Physicians LLC-Miami Valley South Centerville, Ohio, United States, 45459

Miami Valley Hospital South Centerville, Ohio, United States, 45459

Adena Regional Medical Center Chillicothe, Ohio, United States, 45601 University of Cincinnati/Barrett Cancer Center Cincinnati, Ohio, United States, 45219

Case Western Reserve University Cleveland, Ohio, United States, 44106

MetroHealth Medical Center Cleveland, Ohio, United States, 44109

Cleveland Clinic Cancer Center/Fairview Hospital Cleveland, Ohio, United States, 44111

Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210

Mount Carmel East Hospital Columbus, Ohio, United States, 43213

Columbus Oncology and Hematology Associates Inc Columbus, Ohio, United States, 43214

Riverside Methodist Hospital

Columbus, Ohio, United States, 43214

Grant Medical Center

Columbus, Ohio, United States, 43215

The Mark H Zangmeister Center Columbus, Ohio, United States, 43219

Mount Carmel Health Center West

Columbus, Ohio, United States, 43222

Doctors Hospital

Columbus, Ohio, United States, 43228

Good Samaritan Hospital - Dayton Dayton, Ohio, United States, 45406

Miami Valley Hospital

Dayton, Ohio, United States, 45409

Dayton Physicians LLC-Samaritan North Dayton, Ohio, United States, 45415

Miami Valley Hospital North Dayton, Ohio, United States, 45415

Delaware Health Center-Grady Cancer Center Delaware, Ohio, United States, 43015

Grady Memorial Hospital Delaware, Ohio, United States, 43015

Armes Family Cancer Center Findlay, Ohio, United States, 45840

Blanchard Valley Hospital Findlay, Ohio, United States, 45840

Orion Cancer Care Findlay, Ohio, United States, 45840

Cleveland Clinic Cancer Center Independence Independence, Ohio, United States, 44131

Kettering, Ohio, United States, 45409	
Kettering Medical Center Kettering, Ohio, United States, 45429	
OhioHealth Mansfield Hospital Mansfield, Ohio, United States, 44903	
Cleveland Clinic Cancer Center Mansfield Mansfield, Ohio, United States, 44906	
Marietta Memorial Hospital Marietta, Ohio, United States, 45750	
OhioHealth Marion General Hospital Marion, Ohio, United States, 43302	
Hillcrest Hospital Cancer Center Mayfield Heights, Ohio, United States, 44124	
Knox Community Hospital Mount Vernon, Ohio, United States, 43050	
Licking Memorial Hospital Newark, Ohio, United States, 43055	
University Hospitals Parma Medical Center Parma, Ohio, United States, 44129	
Southern Ohio Medical Center Portsmouth, Ohio, United States, 45662	
Ireland Cancer Center at Firelands Regional Medical Center Sandusky, Ohio, United States, 44870	
North Coast Cancer Care Sandusky, Ohio, United States, 44870	
Cleveland Clinic Cancer Center Strongsville Strongsville, Ohio, United States, 44136	
ProMedica Flower Hospital Sylvania, Ohio, United States, 43560	
University of Toledo Toledo, Ohio, United States, 43614	
South Pointe Hospital Warrensville Heights, Ohio, United States, 44122	
Saint Ann's Hospital Westerville, Ohio, United States, 43081	
Cleveland Clinic Wooster Family Health and Surgery Center Wooster, Ohio, United States, 44691	
Genesis Healthcare System Cancer Care Center Zanesville, Ohio, United States, 43701	
United States, Oklahoma	
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States, 73104	
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma, United States, 73120	

United States, Oregon

1/10/2019

Providence Portland Medical Center

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th.
Portland, Oregon, United States, 97213

Kaiser Permanente Northwest Portland, Oregon, United States, 97227

Oregon Health and Science University Portland, Oregon, United States, 97239

United States, Pennsylvania

1/10/2019

Abington Memorial Hospital Abington, Pennsylvania, United States, 19001

Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania, United States, 18103

Saint Luke's University Hospital-Bethlehem Campus Bethlehem, Pennsylvania, United States, 18015

Geisinger Medical Center

Danville, Pennsylvania, United States, 17822

Ephrata Cancer Center

Ephrata, Pennsylvania, United States, 17522

Ephrata Community Hospital

Ephrata, Pennsylvania, United States, 17522

The Regional Cancer Center Erie, Pennsylvania, United States, 16505

Adams Cancer Center

Gettysburg, Pennsylvania, United States, 17325

Cherry Tree Cancer Center

Hanover, Pennsylvania, United States, 17331

Geisinger Medical Center-Cancer Center Hazleton Hazleton, Pennsylvania, United States, 18201

Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850

Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States, 15212

West Penn Hospital

Pittsburgh, Pennsylvania, United States, 15224

University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232

Geisinger Cancer Services-Pottsville

Pottsville, Pennsylvania, United States, 17901

Reading Hospital

West Reading, Pennsylvania, United States, 19611

Wexford Health and Wellness Pavilion

Wexford, Pennsylvania, United States, 15090

Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania, United States, 18711

UPMC Susquehanna

Williamsport, Pennsylvania, United States, 17701

WellSpan Health-York Cancer Center

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma Th...

York, Pennsylvania, United States, 17403

WellSpan Health-York Hospital York, Pennsylvania, United States, 17403

United States, Rhode Island

Newport Hospital

Newport, Rhode Island, United States, 02840

Rhode Island Hospital

Providence, Rhode Island, United States, 02903

Miriam Hospital

Providence, Rhode Island, United States, 02906

United States, South Carolina

AnMed Health Cancer Center Anderson, South Carolina, United States, 29621

Roper Hospital

Charleston, South Carolina, United States, 29401

- Charleston Hematology Oncology Associates-Roper Charleston, South Carolina, United States, 29403
- Lowcountry Hematology Oncology PA-North Charleston Charleston, South Carolina, United States, 29406

Bon Secours Saint Francis Hospital Charleston, South Carolina, United States, 29414

- Charleston Hematology Oncology Associates PA-Saint Francis Charleston, South Carolina, United States, 29414
- Lowcountry Hematology Oncology PA-West Ashley Charleston, South Carolina, United States, 29414
- Saint Francis Cancer Center Greenville, South Carolina, United States, 29607

Lowcountry Hematology Oncology PA-Mount Pleasant Mount Pleasant, South Carolina, United States, 29464

United States, South Dakota

Rapid City Regional Hospital Rapid City, South Dakota, United States, 57701

Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota, United States, 57104

Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota, United States, 57117-5134

United States, Tennessee

The West Clinic - Wolf River Germantown, Tennessee, United States, 38138

The West Clinic - Mid-Town

Memphis, Tennessee, United States, 38104

University of Tennessee Health Science Center Memphis, Tennessee, United States, 38163

Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232

United States, Texas

Texas Oncology - Central Austin Cancer Center Austin, Texas, United States, 78731

Baylor University Medical Center Dallas, Texas, United States, 75246

M D Anderson Cancer Center Houston, Texas, United States, 77030

United States, Utah

American Fork Hospital / Huntsman Intermountain Cancer Center American Fork, Utah, United States, 84003

Sandra L Maxwell Cancer Center Cedar City, Utah, United States, 84720

Logan Regional Hospital Logan, Utah, United States, 84321

Intermountain Medical Center Murray, Utah, United States, 84107

- McKay-Dee Hospital Center Ogden, Utah, United States, 84403
- Utah Valley Regional Medical Center Provo, Utah, United States, 84604

Dixie Medical Center Regional Cancer Center Saint George, Utah, United States, 84770

Utah Cancer Specialists-Salt Lake City Salt Lake City, Utah, United States, 84106

Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States, 84112

LDS Hospital

Salt Lake City, Utah, United States, 84143

South Jordan Health Center South Jordan, Utah, United States, 84009

United States, Vermont

Central Vermont Medical Center/National Life Cancer Treatment Berlin, Vermont, United States, 05602

University of Vermont Medical Center Burlington, Vermont, United States, 05401

University of Vermont College of Medicine Burlington, Vermont, United States, 05405

United States, Virginia

Centra Lynchburg Hematology-Oncology Clinic Inc Lynchburg, Virginia, United States, 24501

Virginia Cancer Institute

Richmond, Virginia, United States, 23230

Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298

VCU Community Memorial Health Center South Hill, Virginia, United States, 23970

United States, Washington

Providence Regional Cancer System-Aberdeen Aberdeen, Washington, United States, 98520

Providence Regional Cancer System-Centralia Centralia, Washington, United States, 98531

Providence Regional Cancer Partnership Everett, Washington, United States, 98201

Providence Regional Cancer System-Lacey Lacey, Washington, United States, 98503

PeaceHealth Saint John Medical Center Longview, Washington, United States, 98632

Kaiser Permanente Washington Seattle, Washington, United States, 98112

Swedish Medical Center-First Hill Seattle, Washington, United States, 98122-4307

Providence Regional Cancer System-Shelton Shelton, Washington, United States, 98584

PeaceHealth Southwest Medical Center Vancouver, Washington, United States, 98664

Providence Saint Mary Regional Cancer Center Walla Walla, Washington, United States, 99362

Providence Regional Cancer System-Yelm Yelm, Washington, United States, 98597

United States, West Virginia

United Hospital Center Bridgeport, West Virginia, United States, 26330

West Virginia University Charleston Division Charleston, West Virginia, United States, 25304

West Virginia University Healthcare Morgantown, West Virginia, United States, 26506

Camden Clark Medical Center Parkersburg, West Virginia, United States, 26101

United States, Wisconsin

Langlade Hospital and Cancer Center Antigo, Wisconsin, United States, 54409

Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin, United States, 53105

Marshfield Clinic-Chippewa Center Chippewa Falls, Wisconsin, United States, 54729

Marshfield Clinic Cancer Center at Sacred Heart Eau Claire, Wisconsin, United States, 54701

Saint Agnes Hospital/Agnesian Cancer Center Fond Du Lac, Wisconsin, United States, 54935

Aurora Health Center-Fond du Lac Fond Du Lac, Wisconsin, United States, 54937

Aurora Health Care Germantown Health Center Germantown, Wisconsin, United States, 53022 Aurora Cancer Care-Grafton Grafton, Wisconsin, United States, 53024

Green Bay Oncology at Saint Vincent Hospital Green Bay, Wisconsin, United States, 54301-3526

Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin, United States, 54301

Green Bay Oncology Limited at Saint Mary's Hospital Green Bay, Wisconsin, United States, 54303

Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin, United States, 54303

Aurora BayCare Medical Center Green Bay, Wisconsin, United States, 54311

Aurora Cancer Care-Kenosha South Kenosha, Wisconsin, United States, 53142

Gundersen Lutheran Medical Center La Crosse, Wisconsin, United States, 54601

University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792

Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin, United States, 54143

Bay Area Medical Center Marinette, Wisconsin, United States, 54143

Marshfield Clinic

Marshfield, Wisconsin, United States, 54449

- Community Memorial Hospital Menomonee Falls, Wisconsin, United States, 53051
- Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin, United States, 53209

Wheaton Franciscan Healthcare - Saint Joseph Milwaukee, Wisconsin, United States, 53210

Aurora Saint Luke's Medical Center Milwaukee, Wisconsin, United States, 53215

Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226

- Aurora Sinai Medical Center Milwaukee, Wisconsin, United States, 53233
- Marshfield Clinic-Minocqua Center Minocqua, Wisconsin, United States, 54548
- Cancer Center of Western Wisconsin New Richmond, Wisconsin, United States, 54017
- Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin, United States, 54154

Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin, United States, 54904

Aurora Cancer Care-Racine Racine, Wisconsin, United States, 53406

Lakeview Medical Center-Marshfield Clinic

1	/1	0	/20)1	9
Т	/ 1	U	/20	11	Э

Rice Lake, Wisconsin, United States, 54868

Marshfield Clinic-Rice Lake Center Rice Lake, Wisconsin, United States, 54868

HSHS Saint Nicholas Hospital Sheboygan, Wisconsin, United States, 53081

Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin, United States, 53081

Ascension Saint Michael's Hospital Stevens Point, Wisconsin, United States, 54481

Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin, United States, 54235-1495

Green Bay Oncology - Sturgeon Bay Sturgeon Bay, Wisconsin, United States, 54235

Aurora Medical Center in Summit Summit, Wisconsin, United States, 53066

Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin, United States, 54241

Aspirus Regional Cancer Center Wausau, Wisconsin, United States, 54401

Marshfield Clinic-Wausau Center Wausau, Wisconsin, United States, 54401

Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin, United States, 53226

Aurora West Allis Medical Center West Allis, Wisconsin, United States, 53227

Marshfield Clinic - Weston Center Weston, Wisconsin, United States, 54476

Aspirus UW Cancer Center Wisconsin Rapids, Wisconsin, United States, 54494

Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids, Wisconsin, United States, 54494

United States, Wyoming

Big Horn Basin Cancer Center Cody, Wyoming, United States, 82414

Billings Clinic-Cody Cody, Wyoming, United States, 82414

Welch Cancer Center Sheridan, Wyoming, United States, 82801

Canada, British Columbia

BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6

Canada, New Brunswick

The Vitalite Health Network - Dr Leon Richard Oncology Centre Moncton, New Brunswick, Canada, E1C 8X3

Canada, Ontario

Royal Victoria Regional Health Centre

1/10/201	9
----------	---

Barrie, Ontario, Canada, L4M 6M2

Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2

Kingston Health Sciences Centre Kingston, Ontario, Canada, K7L 2V7

Grand River Regional Cancer Centre at Grand River Hospital Kitchener, Ontario, Canada, N2G 1G3

London Regional Cancer Program London, Ontario, Canada, N6A 4L6

Trillium Health Partners - Credit Valley Hospital Mississauga, Ontario, Canada, L5M 2N1

Lakeridge Health Oshawa Oshawa, Ontario, Canada, L1G 2B9

Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario, Canada, K1H 8L6

Algoma District Cancer Program Sault Area Hospital Sault Ste Marie, Ontario, Canada, P6B 0A8

Thunder Bay Regional Health Science Centre Thunder Bay, Ontario, Canada, P7B 6V4

Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5

University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9

Windsor Regional Cancer Centre Windsor, Ontario, Canada, N8W 2X3

Canada, Quebec

Hopital de la Cite-de-la-Sante Laval, Quebec, Canada, H7M 3L9

The Research Institute of the McGill University Health Centre (MUHC) Montreal, Quebec, Canada, H3H 2R9

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) Quebec City, Quebec, Canada, G1R 2J6

Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Sherbrooke, Quebec, Canada, J1H 5N4

Canada, Saskatchewan

Allan Blair Cancer Centre Regina, Saskatchewan, Canada, S4T 7T1

Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada, S7N 4H4

Ireland

Saint Vincent's University Hospital Dublin, Co Dublin, Ireland, 4

University College Hospital Galway Galway, Co Galway, Ireland

University Hospital Waterford Waterford, Co Waterford, Ireland, 9

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators

Principal Investigator: Kenneth Grossmann Southwest Oncology Group

More Information

Go to 💌

Responsible Party:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT02506153 History of Changes
Other Study ID Numbers:	NCI-2014-02676
	NCI-2014-02676 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
	S1404
	S1404 (Other Identifier: SWOG)
	S1404 (Other Identifier: CTEP)
	U10CA180888 (U.S. NIH Grant/Contract)
First Posted:	July 23, 2015 Key Record Dates
Last Update Posted:	January 7, 2019
Last Verified:	December 2018

Additional relevant MeSH terms:

Melanoma